CSL Cuts FY26 Guidance, Flags Csl $5 Billion Impairments

csl cut its FY26 guidance and flagged around $5 billion in additional asset impairments after a 90-day interim CEO review. The move lands as investors weigh a slower path to profit against a business that still has demand in plasma, vaccines, and immunoglobulin.

Gordon Naylor said, "Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise." He added, "As a result, we have now revised down our 2026 financial year guidance."

Naylor's 90-day review

90-day review findings pointed to a business that remains operationally strong while the earnings bridge is taking longer to cross. Naylor said, "CSL's culture and people continue to be first class, the industry is stable and growing and the company has evident strengths in plasma collections and influenza vaccines."

$5 billion in additional asset impairments sits alongside that guidance cut, which makes the near-term profit reset sharper than a routine forecast trim. CSL said its core business in plasma collection and influenza vaccines remains strong, and that ongoing demand growth continues in key markets, but short-term revenue has been hit by price pressure and changes in market dynamics.

CSL Behring and Seqirus

CSL said US Immunoglobulin and Albumin product segments are seeing stable or rising demand, while CSL Seqirus is tracking moderately ahead of earlier forecasts for the year. The company also expects revenue growth in CSL Behring in the second half of FY26, which gives the cut guidance a later recovery path rather than an immediate rebound.

$500 million to $550 million in annual savings by FY28 remains the target for CSL's transformation and efficiency program. Naylor said, "I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success."

August 2026 update

49% is how much CSL shares have declined over the past 12 months, even as the S&P/ASX 200 Index rose 6% over the same period. That gap leaves the latest impairment charge and guidance reset carrying more weight for shareholders than the usual earnings update.

1 July 2026 is the date commercial leadership is set to transition to Diego Sacristan, and CSL said it will provide a further update with full-year results in August 2026. For now, the message is simple: the company is still growing, but the profit benefits from that growth are arriving later than planned.